![Novavax to hunt US authorization of its coronavirus vaccine by the tip of the 12 months Novavax to hunt US authorization of its coronavirus vaccine by the tip of the 12 months](https://clpnewsblog.com/wp-content/uploads/https://cdn.cnn.com/cnnnext/dam/assets/211105182643-novavax-fda-authorization-vial-super-tease.jpg)
“We’ll have a file in the US hopefully before the end of the year,” Erck said.
If the FDA gives the green light, the first 100 million doses of the protein-based vaccine will be ready to ship following authorization, Erck said.
“In the US, the primary market I think in 2022 is going to be to supply a vaccine, our normal two-dose regimen, to a lot of people who have been hesitant to get other vaccines,” Erck said. “And to provide a booster.”
The Novavax coronavirus vaccine could be used to boost someone who originally received the Pfizer/BioNTech, Moderna or Johnson & Johnson vaccines, Erck said.
“We’ve actually filed in nine regulatory agencies just in the past half-dozen weeks,” Erck said. “And that resulted in our first one where we got approval.”